Eluminex Acquires Global Rights to Therapy for Rare Genetic Blindness

Suzhou Eluminex Biosciences, an ophthalmology company, acquired global rights to a novel oral therapy for childhood blindness and night blindness in early dry AMD from Seattle 's Retinagenix. The candidate, zuretinol acetate, is being developed to treat rare forms of childhood blindness in patients with Leber's Congenital Amaurosis or Retinitis Pigmentosa caused by mutations of the RPE65 or LRAT gene. Zuretinol is scheduled to start pediatric Phase IIb/III trial later in 2022. More details.... Share this with colleagues: // //